Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS for Hydrocephalus in Neonates and Infants
NCT06693752Phase 2Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Nov 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulfur hexafluoride lipid type a microspheres in hydrocephalus, sponsored by Children's Hospital of Philadelphia. Primary endpoints: Feasibility of brain contrast-enhanced ultrasound (CEUS) examinations up to 2 years and Safety of brain contrast-enhanced ultrasound (CEUS) examinations up to 2 years. Started Nov 2026; status: recruiting.
02
Drugs
sulfur hexafluoride lipid type a microspheres
03
Conditions
hydrocephalus
Beyond the preview
Go deeper on NCT06693752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693752.